Law360, New York (September 25, 2009, 4:34 PM ET) -- The U.S. Food and Drug Administration has ordered the labels for Merck & Co. Inc.'s diabetes treatments Januvia and Janumet to be updated to inform the public about the drugs' risk of leading to acute pancreatitis.
Januvia, also known as sitagliptin, and Janumet, known as sitagliptin/ metformin, are approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Sitagliptin is the first in a new class of diabetic drugs called dipeptidyl peptidase-4 inhibitors.
The FDA said Friday...
Merck Diabetes Drugs Include Pancreatitis Risk: FDA
To view the full article, take a free trial now.
